Disposition of 1909 shares by Bizily Scott of 4D Molecular at 30.0 subject to Rule 16b-3

FDMT Stock  USD 7.50  0.12  1.57%   
Slightly above 66% of 4D Molecular's investor base is looking to short. The analysis of the overall investor sentiment regarding 4D Molecular Therapeutics suggests that many traders are alarmed. 4D Molecular's investing sentiment can be driven by a variety of factors including economic data, 4D Molecular's earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by 4D Molecular TherapeuticsInc Officer: Chief Legal Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Disposition of 1909 common stock at 30.0 of 4D Molecular by Bizily Scott on 27th of February 2024. This event was filed by 4D Molecular TherapeuticsInc with SEC on 2024-02-27. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

4D Molecular's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the 4D Molecular's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

4D Molecular Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards 4D Molecular can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

4D Molecular Fundamental Analysis

We analyze 4D Molecular's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 4D Molecular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 4D Molecular based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

EBITDA

EBITDA Comparative Analysis

4D Molecular is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

4D Molecular Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 4D Molecular stock to make a market-neutral strategy. Peer analysis of 4D Molecular could also be used in its relative valuation, which is a method of valuing 4D Molecular by comparing valuation metrics with similar companies.

Peers

4D Molecular Related Equities

PASGPassage Bio   20.97   
0%
100.0%
REPLReplimune   8.45   
0%
40.0%
GOSSGossamer Bio   6.06   
0%
28.0%
LYRALyra Therapeutics   5.26   
0%
25.0%
NVCTNuvectis Pharma   4.04   
0%
19.0%
IPSCCentury Therapeutics   3.85   
0%
18.0%
RVMDRevolution Medicines   1.97   
0%
9.0%
CGEMCullinan Oncology   1.83   
0%
8.0%
EWTXEdgewise Therapeutics   0.31   
0%
1.0%
STOKStoke Therapeutics   0.08   
1.0%
0%
BMEABiomea Fusion   0.58   
2.0%
0%
MLYSMineralys Therapeutics,   1.42   
6.0%
0%
BDTXBlack Diamond   1.59   
7.0%
0%
AKROAkero Therapeutics   1.92   
9.0%
0%
KRONKronos Bio   2.25   
10.0%
0%
CCCCC4 Therapeutics   4.34   
20.0%
0%

Additional Tools for FDMT Stock Analysis

When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.